INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 140 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2017. The put-call ratio across all filers is 1.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,793,000 | -62.9% | 38,536 | -54.5% | 0.01% | -60.9% |
| Q2 2022 | $4,836,000 | -25.2% | 84,720 | -19.9% | 0.02% | +9.5% |
| Q1 2022 | $6,469,000 | +1947.2% | 105,728 | +428.6% | 0.02% | +2000.0% |
| Q3 2017 | $316,000 | +96.3% | 20,000 | +53.8% | 0.00% | 0.0% |
| Q2 2017 | $161,000 | -20.3% | 13,000 | +150.0% | 0.00% | 0.0% |
| Q2 2016 | $202,000 | -24.6% | 5,200 | -22.4% | 0.00% | 0.0% |
| Q3 2015 | $268,000 | -74.2% | 6,700 | -79.4% | 0.00% | -80.0% |
| Q2 2015 | $1,037,000 | -73.6% | 32,450 | -80.3% | 0.01% | -72.2% |
| Q1 2015 | $3,935,000 | – | 164,797 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 424,500 | $13,499,000 | 5.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $6,360,000 | 3.70% |
| Asymmetry Capital Management, L.P. | 130,654 | $4,155,000 | 1.90% |
| Altium Capital Management LP | 153,348 | $4,876,000 | 1.82% |
| Sofinnova Investments, Inc. | 848,162 | $26,972,000 | 1.61% |
| Bellevue Group AG | 3,659,919 | $116,386,000 | 1.33% |
| Eversept Partners, LP | 356,235 | $11,328,273 | 1.33% |
| Rhenman & Partners Asset Management AB | 500,000 | $15,900,000 | 1.30% |
| GENERAL AMERICAN INVESTORS CO INC | 347,497 | $11,050,000 | 1.09% |
| WASATCH ADVISORS LP | 6,333,900 | $201,418,000 | 0.99% |